NEW YORK (GenomeWeb News) — EuroGentest is expected to announce next week that it is evaluating a pyrophosphorolysis activated polymerization assay for prenatal screening through Europe’s Special Non-invasive Advances in Fetal and NeoNatal Evaluation Network (SAFE) and another of its Excellence programs.

 

The PAP assay, a non-invasive prenatal screening test, uses maternal plasma to detect rare mutations and to determine fetal sex.